CD274 and neoplasm: Furthermore, while different predictive biomarkers for immunotherapy have been investigated, including PD-L1, MSI/dMMR, and tumor mutational burden (TMB), MSI is currently the only pan-tumor biomarker for an approved oncological treatment.